Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study

Area of Science:

• Psychiatry
• Clinical Pharmacology

Background:

• Schizophrenia treatment often involves balancing efficacy with side effect profiles.
• Haloperidol is a conventional antipsychotic with known extrapyramidal side effects.
• Remoxipride is a newer antipsychotic with a potentially different side effect profile.

Purpose of the Study:

• To compare the efficacy and safety of remoxipride versus haloperidol in patients with schizophrenia.
• To evaluate treatment outcomes using standardized rating scales.
• To identify reasons for premature treatment discontinuation.

Main Methods:

• A double-blind, multicenter, parallel-group trial involving 92 schizophrenia patients.
• Six-week treatment period with washout.
• Comparison of Clinical Global Impression (CGI) and Brief Psychiatric Rating Scale (BPRS) scores.
• Assessment of treatment-emergent extrapyramidal symptoms and concentration difficulties.

Main Results:

• Both remoxipride and haloperidol groups showed significant symptom improvement (CGI and BPRS scores).
• No significant difference in overall treatment outcome between the two groups.
• Significantly more frequent and severe extrapyramidal symptoms and concentration difficulties in the haloperidol group.
• Severe extrapyramidal side effects (haloperidol) and clinical ineffectiveness (remoxipride) were primary reasons for discontinuation.

Conclusions:

• Remoxipride and haloperidol demonstrate comparable efficacy in schizophrenia treatment.
• Remoxipride is associated with a lower incidence of extrapyramidal symptoms and concentration difficulties compared to haloperidol.
• The side effect profile may influence treatment adherence and discontinuation rates.